Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $38.03M (cash outflow) rose 5.9% year over year, ahead of the -21.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 26.2% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.
Context
- Free cash flow amounted to 9986.5% of revenue in FY2025, down 88516.5 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.9% holds above the trailing-twelve-month pace of -21.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (129.83M) USD
- Year-over-year change
- +34.1%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.83M) | +34.1% |
| FY2024 | 2024-12-31 | (197.01M) | +0.5% |
| FY2023 | 2023-12-31 | (197.9M) | -70.6% |
| FY2022 | 2022-12-31 | (115.99M) | -42.9% |
| FY2021 | 2021-12-31 | (81.19M) | — |
Free Cash Flow vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -21.8% is the lowest of 7, against a peer median of +35.5%.
- Free cash flow amounts to 10148.8% of revenue for INBX, versus a peer median of 640.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $259.45M USD | +42.8% | +26.5% | 231652.7% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $204.13M USD | +68.4% | — | 640.1% |
| LTM Mar 2026 | €188.49M EUR | +10.8% | — | 505.4% | |
| LTM Mar 2026 | $131.94M USD | -21.8% | +3.8% | 10148.8% | |
| LTM Mar 2026 | $98.51M USD | +28.3% | -1.2% | 5365.2% | |
| LTM Mar 2026 | $78.49M USD | +68.7% | +19.0% | 363.2% | |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $65.66M USD | +4.1% | -14.8% | — |
| Peer median (excluding INBX) | — | +35.5% | +8.9% | 640.1% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (81.77M) | (145.23M) | (239.73M) | 1.69B | (140.06M) |
| Depreciation & Amortization | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| Deferred Income Tax | (9K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.05M | 20.45M | 24.85M | 58.52M | 11.14M |
| Change in Working Capital | (17.52M) | 3.16M | 15.35M | 52.05M | (7.61M) |
| Accounts Receivables | (167K) | 130K | (521K) | 381K | 243K |
| Inventory | (11.03M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.64M) | (705K) | 2.11M | 17.9M | (3.3M) |
| Other Working Capital | (1.67M) | 3.74M | 13.76M | 33.77M | (4.56M) |
| Other Non-Cash Items | 2.73M | 5.09M | 5.03M | (1.99B) | 4.25M |
| Operating Cash Flow | (80.32M) | (115.3M) | (193.31M) | (194.41M) | (129.79M) |
| Capital Expenditures | (864K) | (686K) | (4.59M) | (2.6M) | (31K) |
| Acquisitions (Net) | 55K | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (809K) | (686K) | (4.59M) | (2.6M) | (28K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 99.84M |
| Common Stock Issued | 40.2M | 129.74M | 201.96M | 71.68M | 1.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 83.77M | 128.81M | 0 | 0 | 0 |
| Financing Cash Flow | 83.77M | 258.55M | 201.96M | 71.68M | 101.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.64M | 142.56M | 4.06M | (125.33M) | (28.38M) |
| Free Cash Flow | (81.19M) | (115.99M) | (197.9M) | (197.01M) | (129.83M) |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.